Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metastatic Breast Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,106 result(s) found for: Metastatic Breast Cancer. Displaying page 1 of 56.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002120-83 Sponsor Protocol Number: ICO-N-2016-02 Start Date*: 2016-10-05
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU
    Full Title: Study evaluation of 2nd hormone line response by -[18F]fluoro-17β-œstradiol (FES) PET/CT in metastatic breast cancer patients
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10007305 Carcinoma breast LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005184-42 Sponsor Protocol Number: CLEE011A2412B Start Date*: 2022-04-15
    Sponsor Name:NOVARTIS PHARMA AG
    Full Title: A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study
    Medical condition: HR+, HER2- advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006430-10 Sponsor Protocol Number: CTKI258A2202 Start Date*: 2009-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer.
    Medical condition: In female patients with FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003220-52 Sponsor Protocol Number: CC-486-BRSTM-001 Start Date*: 2015-03-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal...
    Medical condition: Postmenopausal female subjects with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer, who have progressed on an aromatase inhibi...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006315 Breast tumor malignant LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006204 Breast carcinoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006283 Breast neoplasm malignant female LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002759-15 Sponsor Protocol Number: XEL-CONT-VS ESTANDAR Start Date*: 2004-11-15
    Sponsor Name:Dr. Miguel Martín
    Full Title: Randommized Phase II study of the continuous treatment vs. standard treatment with capecitabine in metastatic breast cancer patients
    Medical condition: METASTATIC BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027475 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000698-57 Sponsor Protocol Number: MDV3100-11 Start Date*: 2013-09-01
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed) IE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-005885-36 Sponsor Protocol Number: 0007 Start Date*: 2006-02-09
    Sponsor Name:AZIENDA USL DI FORLI
    Full Title: Dose finding study of Liposomal Doxorubicin Myocet in combination with Capecitabine Xeloda in the treatment of metastatic breast cancer patients
    Medical condition: Metastatic breast cancer pretreated
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005592-17 Sponsor Protocol Number: P05059 Start Date*: 2006-12-14
    Sponsor Name:Schering-Plough AB Sweden
    Full Title: Caelyx® in Breast Cancer in the Elderly Pegylated Liposomal Doxorubicin (Caelyx®) as monotherapy in elderly patients with locally advanced and/or metastatic breast cancer
    Medical condition: Locally advanced and/or metastatic breast cancer, not amenable to surgery.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer PT
    Population Age: Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002736-28 Sponsor Protocol Number: GINECO-BR106 Start Date*: 2007-09-19
    Sponsor Name:ARCAGY-GINECO
    Full Title: A multicentre study DOGMES: Liposomal doxorubicin in geriatric oncology - Metastatic breast cancer - first line treatment by pegylated liposomal doxorubicin in patients of more than 70 years old wi...
    Medical condition: Breast cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017788-40 Sponsor Protocol Number: KEO09069EST Start Date*: 2010-10-20
    Sponsor Name:CRLCC Alexis Vautrin
    Full Title: Etude de phase II randomisée multicentrique évaluant l'efficacité d’estramustine phosphate (Estracyt ®) chez des patientes présentant un cancer du sein métastatique HER2- / RH+ ayant déjà reçu un t...
    Medical condition: Metastases breast cancer in women already treated with aromatase inhibitors.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003620-11 Sponsor Protocol Number: SBG-2-01 Start Date*: 2006-10-10
    Sponsor Name:Biotec Pharmacon ASA
    Full Title: A phase I/II study to assess the effect of soluble beta-1,3/1,6-glucan in combination with standard therapy in patients with breast cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004112-11 Sponsor Protocol Number: C/31/2014 Start Date*: 2015-05-20
    Sponsor Name:Imperial College London
    Full Title: ALERT: A phase II study of alternating eribulin and hormonal therapy in pre-treated ER+ve breast cancer
    Medical condition: Patients with locally advanced or metastatic oestrogen receptor positive (ER+ve) breast cancer who have received at least one hormonal therapy and at least one chemotherapy in the metastatic setting.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002665-35 Sponsor Protocol Number: 190619 Start Date*: 2019-10-14
    Sponsor Name:Mikkel Holm Vendelbo
    Full Title: 16α-18F-fluor-17β-estradiol PET/CT for detection of estrogen receptor positive liver metastases in breast cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006168-71 Sponsor Protocol Number: SF2- Gem/tax Start Date*: 2006-02-16
    Sponsor Name:A.S.L. 2
    Full Title: Phase II study with gemcitabine/docetaxel first line in women with metastatic breast cancer
    Medical condition: oncological patients only
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006262-28 Sponsor Protocol Number: IEO S438/508 Start Date*: 2009-06-03
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Allogeneic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Refractory “Triple Negative”...
    Medical condition: Patients with Refractory “Triple Negative” Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006025-27 Sponsor Protocol Number: IEOS380/607 Start Date*: 2008-11-10
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in adv...
    Medical condition: advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002525-29 Sponsor Protocol Number: UC-0140/1206 Start Date*: 2013-03-08
    Sponsor Name:UNICANCER
    Full Title: A phase II trial evaluating the Activity of Abiraterone Acetate plus Prednisone in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer.
    Medical condition: Molecular apocrine locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001545-42 Sponsor Protocol Number: B9E-IT-S376 Start Date*: 2005-07-13
    Sponsor Name:ELI LILLY
    Full Title: A Randomized Phase III Trial of Gemcitabine and Docetaxel versus Gemcitabine and Paclitaxel in Patients with Metastatic Breast Cancer: a comparison of different schedules
    Medical condition: Metatstatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001054-34 Sponsor Protocol Number: D0816C00018 Start Date*: 2018-01-11
    Sponsor Name:AstraZeneca AB
    Full Title: LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-...
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) FR (Ongoing) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005683-87 Sponsor Protocol Number: VNBCAPTAX Start Date*: 2006-02-22
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: VINORELBINA CAPECITABIME PACLITAXEL AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS PRETREATED WITH ADJUVANT ANTHRACYCLINES
    Medical condition: METASTATIC BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 10:19:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA